The German biotech firm Evotec has secured a significant cash infusion through a major asset sale, yet the market remains skeptical. The company’s ongoing restructuring efforts, while ahead of schedule on cost-cutting, have yet to translate into operational strength. All eyes are now on a pivotal date in early 2026 for proof that these moves will restore profitability.
Liquidity Boost from Strategic Divestment
Evotec has finalized the sale of its biologics site in Toulouse to Sandoz. This transaction delivers an immediate financial benefit, with approximately $350 million US in cash proceeds. Furthermore, the agreement includes potential future inflows of more than $300 million US tied to licensing, development revenue, and success-based milestone payments over the coming years.
This deal aligns with the company’s stated strategic shift. Evotec aims to operate with a leaner capital structure, focusing more on scaling through technology monetization. As part of the agreement, Sandoz receives a perpetual license for continuous biologics manufacturing.
Cost-Cutting Exceeds Targets Amid Mixed Operational Results
The company’s efficiency drive is progressing faster than anticipated. Evotec reports that its savings program is exceeding the original plan, with projected annual savings of more than €60 million by 2025—roughly double the initial target. To achieve this, around 280 positions have been eliminated and several sites consolidated, aiming to reduce ongoing costs by €40 million annually from 2025 onward.
Should investors sell immediately? Or is it worth buying Evotec?
Operationally, however, the picture is split. For the first nine months of 2025, group revenue declined to €535.1 million, a decrease of 7.1% year-over-year. This was driven by a sharp contrast between business segments: revenue from Just – Evotec Biologics grew 11.3% to €143.4 million, while the Discovery & Preclinical Development unit saw revenue fall 12.3% to €392.1 million. The adjusted EBITDA for the nine-month period stood at –€16.9 million.
Despite recent challenges, management reaffirms its long-term ambitions. The company’s target for the period from 2024 to 2028 is a revenue compound annual growth rate (CAGR) of 8–12% and an adjusted EBITDA margin exceeding 20% by 2028.
Share Price Under Pressure Ahead of Key Report
Market uncertainty continues to weigh heavily on Evotec’s equity. Shares closed at €5.66 in the latest session. The stock shows a decline of –12.68% over the past 30 days and is down –20.67% over a 12-month horizon. The current price sits approximately –32% below its 52-week high of €8.32, underscoring the significant erosion of investor confidence.
This context makes April 8, 2026, a critical date for the company. On that day, Evotec is scheduled to release its annual report and provide its outlook for 2026. This disclosure will be the definitive test, requiring management to demonstrate that the Toulouse sale and deep cost reductions are not merely bolstering the balance sheet but are also paving a credible path back to sustainable profitability. Until then, the stock is likely to remain under the shadow of weaker performance in the Discovery & Preclinical Development division—the very segment that has recently been the primary drag on overall results.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from March 5 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 5.
Evotec: Buy or sell? Read more here...
